Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus
Abstract
Eleven lots of combined bivalent and trivalent vaccines containing the measles (Moraten), mumps (Jeryl Lynn), and rubella (RA 2713) viruses gave satisfactory results in tests in initially seronegative children (measles, 493 children; mumps, 377; rubella, 586). There was no apparent suppression of antibody response against any of the viruses in the vaccines. The clinical reactions observed were mild and inconsequential. Substitution of the HPV 77-DE strain employed heretofore with the RA 27/3 is technically acceptable and offers the advantage of higher titer, slightly greater seroconversion rate, and more solid immunity against reinfection in nature.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There was no difference in the incidence of common outcomes such as fever, rash, cough, lymphadenopathy, arthralgia, myalgia and anorexia between the MMR vaccine and rubella vaccine, mumps-rubella vaccine, single mumps vaccine, or measles vaccine.
“There was no difference in the incidence of common outcomes such as fever, rash, cough, lymphadenopathy, arthralgia, myalgia and anorexia between the MMR vaccine and rubella vaccine (Makino 1990; Swartz 1974; Weibel 1980), mumps-rubella vaccine (Swartz 1974), single mumps vaccine (Makino 1990) or measles vaccine (Dunlop 1989; Makino 1990).”
From Vaccines for measles, mumps and rubella in children (2012) · cites this paper as Weibel 1980
Cited by
Sorted by citations
Shefer, A. M., & Atkinson, W. W. (2011) · Cited by 647 · see citing works
Vaccines for measles, mumps and rubella in children
Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub3 · Cited by 372 · see citing works
Peltola, H., Heinonen, O. P., Valle, M., Paunio, M., Virtanen, M., Karanko, V., & Cantell, K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312101 · Cited by 344 · see citing works
Adverse Effects of Vaccines: Evidence and Causality
Stratton, K. R., Ford, A. Q., Rusch, E., & Clayton, E. W. (2013) · Cited by 346 · see citing works
FREQUENCY OF TRUE ADVERSE REACTIONS TO MEASLES-MUMPS-RUBELLA VACCINE
Peltola, H., & Heinonen, O. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91044-5 · Cited by 212 · see citing works
Vaccines for measles, mumps, rubella, and varicella in children
Pietrantonj, C. D., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub4 · Cited by 197 · see citing works
History of Vaccine Development
Plotkin, S. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1339-5 · Cited by 131 · see citing works
The History of Rubella and Rubella Vaccination Leading to Elimination
Plotkin, S. A. (2006) · Clinical Infectious Diseases · doi:10.1086/505950 · Cited by 117 · see citing works
Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination
Virtanen, M., Peltola, H., Paunio, M., & Heinonen, O. P. (2000) · PEDIATRICS · doi:10.1542/peds.106.5.e62 · Cited by 105 · see citing works
Vaccines for measles, mumps and rubella in children
Demicheli, V., Jefferson, T., Rivetti, A., & Price, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub2 · Cited by 104 · see citing works
RAPID EFFECT ON ENDEMIC MEASLES, MUMPS, AND RUBELLA OF NATIONWIDE VACCINATION PROGRAMME IN FINLAND
Peltola, H., Kurki, T., Virtanen, M., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92270-1 · Cited by 95 · see citing works
Lievano, F. A., Galea, S. A., Thornton, M., Wiedmann, R. T., Manoff, S. B., Tran, T. N., Amin, M. A., Seminack, M. M., Vagie, K. A., Dana, A., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.057 · Cited by 88 · see citing works
Unintended events following immunization with MMR: a systematic review
Jefferson, T., Price, D., Demicheli, V., & Bianco, E. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00271-8 · Cited by 86 · see citing works
“We included nine cohort studies, comparing MMR with single measles vaccine [5,17,22,27], mumps–rubella vaccine [21], single mumps [5], single rubella [21,23], placebo [24] or no intervention [20,28].”
BackgroundMethodInfluentialImmune responses and vaccination against periodontal infections
Persson, G. R. (2005) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00800.x · Cited by 81 · see citing works
Vaccines for measles, mumps, rubella, and varicella in children
Pietrantonj, C. D., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub5 · Cited by 100 · see citing works
Vaccines for measles, mumps and rubella in children
Demicheli, V., Rivetti, A., Debalini, M. G., & Pietrantonj, C. D. (2013) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.1948 · Cited by 51 · see citing works
Abad, C. L. R., & Safdar, N. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0506-5 · Cited by 48 · see citing works
“It may cause fever (<15 %), transient rashes (5 %), lymphadenopathy (5 % of children and 20 % of adults), or parotitis (<1 %) [65–69].”
BackgroundClinical Trial of a New Trivalent Measles-Mumps-Rubella Vaccine in Young Children
Vesikari, T. (1984) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1984.02140470043013 · Cited by 40 · see citing works
Rubella Immunity and Morbidity: Impact of Different Vaccination Programs in Finland 1979–1992
Ukkonen, P. (1996) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549609027146 · Cited by 40 · see citing works
Kowalzik, F., Faber, J., & Knuf, M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.051 · Cited by 37 · see citing works
Strebel, P. M., Papania, M. J., Dayan, G. H., & Halsey, N. A. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50022-2 · Cited by 132 · see citing works
Strebel, P. M., Papania, M. J., Gastañaduy, P. A., & Goodson, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00037-7 · Cited by 55 · see citing works
Rubella Immunity and Morbidity: Effects of Vaccination in Finland
Ukkonen, P., & von Bonsdorff, C. (1988) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548809032448 · Cited by 32 · see citing works
Strebel, P. M., Papania, M. J., Fiebelkorn, A. P., & Halsey, N. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00028-8 · Cited by 31 · see citing works
Bakshi, S. S., & Cooper, L. Z. (1990) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(16)36909-7 · Cited by 30 · see citing works
Kuter, B. J., Brown, M. L. H., Wiedmann, R. T., Hartzel, J. S., & Musey, L. K. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001241 · Cited by 24 · see citing works
“The safety profile of M-M-RII described in this report is consistent with both the results of prelicensure clinical trials of a first dose as well as postlicensure evaluations of a first and second dose of the vaccine when used in routine clinical practice.(6,7,14,20,22,23) However, none of the 23 studies described in…”
MethodResultSafe Immunization of Allergic Children Against Measles, Mumps, and Rubella
Juntunen‐Backman, K. (1987) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1987.04460100081032 · Cited by 25 · see citing works
McLean, H. Q., Fiebelkorn, A. P., Ogee-Nwankwo, A., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.010 · Cited by 24 · see citing works
Plotkin, S. A., & Reef, S. E. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50033-7 · Cited by 23 · see citing works
Two Doses of MMR Vaccine—Sufficient to Eradicate Measles, Mumps and Rubella?
Fahlgren, K. (1988) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488801600301 · Cited by 23 · see citing works
Development of combination vaccines
Ellis, R. W. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00424-1 · Cited by 22 · see citing works
Ravanfar, P., Satyaprakash, A. K., Creed, R., & Mendoza, N. (2009) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2009.01224.x · Cited by 22 · see citing works
Viruses and salivary gland disease: Are there associations?
Scully, C. M. (1988) · Oral Surgery Oral Medicine Oral Pathology · doi:10.1016/0030-4220(88)90090-4 · Cited by 19 · see citing works
Plotkin, S. A., Reef, S. E., Cooper, L. Z., et al. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00028-6 · Cited by 17 · see citing works
Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months
Forleo‐Neto, E. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00135-7 · Cited by 17 · see citing works
Reef, S. E., & Plotkin, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00038-0 · Cited by 16 · see citing works
Kennedy, R. B., Ovsyannikova, I. G., Vierkant, R. A., et al. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.11.002 · Cited by 13 · see citing works
“In addition, the current two dose vaccination schedule of Measles, Mumps and Rubella vaccine (MMR) results in seroconversion rates to rubella over 95%, but a significant minority of individuals do not seroconvert or develop suboptimal antibody levels after vaccination[16–22].”
BackgroundReef, S. E., & Plotkin, S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00052-3 · Cited by 13 · see citing works
Total elimination of measles in Finland
Heinonen, O. P., Paunio, M., & Peltola, H. (1998) · Annals of Medicine · doi:10.3109/07853899808999395 · Cited by 13 · see citing works
Hoshino, M., Oka, Y., DEGUCHI, M., et al. (1982) · Journal of Biological Standardization · doi:10.1016/s0092-1157(82)80022-x · Cited by 12 · see citing works
Ledogar, R. J., Fleming, J. R., & Andersson, N. (2009) · BMC International Health and Human Rights · doi:10.1186/1472-698x-9-s1-s6 · Cited by 11 · see citing works
“Of 31 studies that met the Cochrane review’s inclusion criteria, we selected those 20 that contained specific numbers of adverse effect cases together with the total study population [13-32].”
Hilleman, M. R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1339-5_23 · Cited by 10 · see citing works
Self-citationÉvaluation de 35 années de vaccination rougeole–oreillons–rubéole en France
Reinert, P., Soubeyrand, B., & Gauchoux, R. (2003) · Archives de Pédiatrie · doi:10.1016/j.arcped.2003.09.028 · Cited by 10 · see citing works
Manufacturing Issues for Multivalent Vaccines
Elliott, A. Y. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44434.x · Cited by 9 · see citing works
Combined Measles, Mumps, and Rubella Vaccines
Hilleman, M. R. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-265-4_9 · Cited by 7 · see citing works
Self-citationVaccination with a live RA 27/3 strain rubella vaccine (Rudivax), a follow-up study
Suni, J. I., Meurman, O. H., Hirvonen, P., et al. (1984) · Vaccine · doi:10.1016/0264-410x(84)90045-8 · Cited by 7 · see citing works
Moss, W. J., & Strebel, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00038-4 · Cited by 6 · see citing works
Wrong About Vaccine Safety: A Review of Andrew Wakefield’s “Callous Disregard”
Harrison, J. A. (2013) · The Open Vaccine Journal · doi:10.2174/1875035420131126002 · Cited by 6 · see citing works
Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine)
Nyaku, M. K., Richardson, E., Martinón‐Torres, F., et al. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003273 · Cited by 5 · see citing works
“), which was the first combination MMR vaccine licensed in the United States using the HPV77:DE-5 rubella strain.(4,5) M-M-RII has been used in many countries for over 40 years with more than 803 million doses distributed worldwide (Merck & Co.”
MethodEdwards, K. M. (1993) · Current Problems in Pediatrics · doi:10.1016/0045-9380(93)90015-5 · Cited by 5 · see citing works
Postpartum rubella vaccination for sero-negative women
Alzeidan, R. A., Wahabi, H., Fayed, A. A., et al. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010752 · Cited by 3 · see citing works
The role of editorial peer review in the evaluation of vaccine safety
Jefferson, T. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.012 · Cited by 3 · see citing works
Gao, B.-G., Huang, L.-F., & Xie, P. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0820 · Cited by 2 · see citing works
“Some reports indicate that the diagnosis of mumps can be con fi rmed in the laboratory by the isolation of the mumps virus from specimens, which may re fl ect the e ff ectiveness of MuCV [5 – 7].”
BackgroundConventional and New Generation Combined Vaccines
André, F. E., Stanbury, W. J., & Teuwen, D. E. (1994) · Springer eBooks · doi:10.1007/978-1-4899-1450-7_4 · Cited by 2 · see citing works
Pediatric Combination Vaccines
Vidor, E. J., Hoffenbach, A., & Plotkin, S. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-265-4_1 · Cited by 2 · see citing works
Reef, S. E., & Plotkin, S. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00039-1 · Cited by 1 · see citing works
Measles-Mumps-Rubella Vaccination Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of
Virtanen, M., Peltola, H., Paunio, M., et al. (2012)
Benoist, G., Leruez‐Ville, M., & Ville, Y. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-7020-6956-7.00042-7
Reef, S. E., & Plotkin, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00054-2
Molecular ingredients of an immunogen for long-lasting IgG
Gupta, S. L., Meyer, A. R., Kay-Tsumagari, E., & Cheng, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639371
Maurice Hilleman, Merck’s monument for mankind, a reappraisal
Clercq, E. D. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118102
Serological evaluation of a measles, mumps, and rubella vaccine
Robertson, C. M., Bennett, V. J., Jefferson, N., & Mayon-White, R. T. (1988) · Archives of Disease in Childhood · doi:10.1136/adc.63.6.612 · Cited by 34 · see citing works
- Authors
- Weibel, R. E., Carlson, A. J., Villarejos, V. M., Buynak, E. B., McLean, A. A., & Hilleman, M. R.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Louisiana State University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 1980-11-01
- Volume
- 165
- Issue
- 2
- Pages
- 323-326
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2075074419
- Cited by
- 64
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 1 · 2013: 6 · 2012: 3
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- MMR vaccine, seroconversion, antibody response, vaccine safety, seronegative children, live attenuated vaccine
- MeSH terms
- Antibodies, Viral, Child, Humans, Measles Vaccine, Mumps Vaccine, Rubella Vaccine, Rubella virus, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
